Tag: faces
Gilead’s Truvada faces Teva generics assault amid Descovy switching campaign
When its U.S. patent cliff for HIV med Truvada was still on the horizon, Gilead Sciences won approval for follow-up med Descovy and launched an...
Biogen’s lagging Vumerity, stalled by the pandemic, faces ‘critical’ stretch ahead,...
Biogen’s Tecfidera follow-up Vumerity hit the market late last year, but eight months into the launch, the new multiple sclerosis drug is yet to meaningfully take off.
The drug...